Researchers at Washington University School of Medicine in St. Louis have engineered astrocytes—star-shaped brain cells—to target and remove amyloid beta plaques, a key driver of Alzheimer's disease. This CAR-based approach transforms astrocytes into precise cleaners, offering a fresh take on Alzheimer's immunotherapy with just one injection. In mice, early treatment prevented plaques entirely, while later doses cut existing buildup by half.
How CAR-Astrocytes Target Plaques
Astrocytes naturally tidy the brain but falter under heavy amyloid beta loads during Alzheimer's progression. Scientists added a chimeric antigen receptor (CAR), pulled from cancer therapies, to give these cells a homing device for grabbing plaques. Senior author Marco Colonna, MD, described it as the first time astrocytes cleared amyloid beta effectively in mouse models of the disease.
The team delivered the CAR gene via a harmless virus. This equipped astrocytes to engulf and destroy plaques without broad disruption. First author Yun Chen, PhD, focused on lightening the load for microglia, the brain's stressed immune cells.
Amyloid Beta Clearance in Action
Amyloid beta sticks into plaques that trigger brain shrinkage and memory loss. CAR-astrocytes lock onto these via surface receptors, pulling them in for breakdown. Young mice, primed for plaques by six months, stayed clear after treatment. Older ones with saturated brains dropped plaques 50% in three months versus controls. A MedicalXpress report detailed these mouse results, noting the therapy's stage-specific power.
Edge Over Current Alzheimer's Immunotherapy
Monoclonal antibodies, the go-to drugs, slow amyloid buildup and add roughly 10 months of independence. They demand high-dose infusions every month or so. CAR-astrocytes match that impact with a single shot, shining brightest early on.
Co-author David M. Holtzman, MD, stressed the dosing simplicity in a Washington University news release. The Science journal publication from March 2026 backs the findings with full study data.
Mouse Study Key Findings
Genetically altered mice mimicked human Alzheimer's risk, hitting peak plaques at six months. Preemptive injections kept brains plaque-free. Later treatments halved the mess, with no big side effects spotted yet. Researchers filed patents through WashU's tech office for human potential.
Next Steps in Brain Cell Therapy
Teams aim to tweak CAR-astrocytes for tau proteins and safety boosts, ensuring no harm to healthy brain functions. The homing device tweak could shift focus to brain tumors, where astrocytes might directly attack cancer cells instead of plaques—offering a dual-purpose tool for central nervous system threats. Early action mirrors antibody success but simplifies delivery, potentially easing patient burdens with fewer clinic visits.
Optimization efforts target finer control over CAR expression to hit plaques harder while sparing normal proteins. Human trials could follow patent advancements, building on the mouse success where young brains stayed entirely plaque-free and older ones gained substantial relief. Collaborators plan to test combinations with existing therapies, blending CAR-astrocytes into broader Alzheimer's immunotherapy strategies.
This March 2026 advance hints at broader wins in amyloid beta clearance. It spotlights astrocytes' untapped role in neurodegeneration, paving ways for one-time treatments that extend independence far beyond current options. Researchers see parallels to CAR-T's cancer triumphs, fueling hope for brain disease breakthroughs ahead.